MedTrace Logo

Intranasal Insulin for Weight Management During Smoking Cessation

NCT02028871 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-12-10

Study results available
· View outcomes & findings →

Summary

This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.

Conditions

  • Tobacco Abstinence Syndrome

Interventions

DRUG

Intranasal Insulin

DRUG

Placebo

Sponsors & Collaborators

  • Ajna Hamidovic

    lead OTHER

Principal Investigators

  • Ajna Hamidovic, PharmD · University of New Mexico

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02028871 on ClinicalTrials.gov